Prediction of natalizumab anti-drug antibodies persistency

Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site

(2017) Karin A. van Schie et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

(2017) Tomas Kalincik et al.   LANCET NEUROLOGY

Disease activity return after natalizumab cessation in multiple sclerosis

(2016) Maria Rasenack et al.   Expert Review of Neurotherapeutics

Extended interval dosing of natalizumab in multiple sclerosis

(2016) L Zhovtis Ryerson et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Disease activity return after natalizumab cessation in multiple sclerosis

(2016) Maria Rasenack et al.   Expert Review of Neurotherapeutics

A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort

(2013) O. Outteryck et al.   EUROPEAN JOURNAL OF NEUROLOGY

Fatal neuroinflammation in a case of multiple sclerosis with anti-natalizumab antibodies

(2013) A. Svenningsson et al.   NEUROLOGY

Prediction of antibody persistency from antibody titres to natalizumab

(2012) Poul Erik H Jensen et al.   Multiple Sclerosis Journal

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis

(2012) Anke Vennegoor et al.   Multiple Sclerosis Journal

Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab

(2011) Per Soelberg Sørensen et al.   Multiple Sclerosis Journal

Persistency of neutralizing antibodies depends on titer and interferon-beta preparation

(2011) Harald Hegen et al.   Multiple Sclerosis Journal

Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months

(2010) Begoña Oliver et al.   Multiple Sclerosis Journal

Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products

(2008) Gopi Shankar et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS